References
- Hanks G E, Martz K L, Diamond J J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299–1305
- Forman J D, Kumar R, Haas G, Montie J, Porter A T, Mesina C F. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 8–15
- Zelefsky N J, Leibel S A, Burman C A, Kutcher G J, Harrison A, Happersett L, Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Oncol Biol Phys 1994; 29: 755–761
- Yang F E, Chen G T, Ray P, Vaida F, Chiru P, Hamilton R J, Spelbring D, Abellera M, Vijaykumar S. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1009–1017
- Zelefsky M J, Harrison B S. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 1997; 49: 38–45
- Pilepich M V, Sause W T, Shipley W U, Krall J M, Lawton C A, Grignon D, Al-Sarraf M, Abrams R A, Caplan R, John M J, Rotman M, Cox J D, Doggett R LS, Rubin P. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616–623
- Pilepich M V, Caplan R, Byhardt R W. Phase HI trial of androgen suppression using goserilin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy. Proc Am Soc Clin Oncol 1995; 14: 239A
- Bolla M, Gonzalez D, Warde P, Dubois J B, Mirimanoff R E, Storme G, Bemier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med 1997; 337: 295–300
- Eulau S, Corn B. Combinations of hormones and local advanced therapies in locally advanced prostate carcinoma. Oncology 1996; 10: 1193–1202
- Pollack A, Zagars G K, Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32: 13–20
- Nakfoor B M, Prince E A, Shipley W U, Zeitman A L. A randomized trial comparing local tumor control following irradiation alone versus combined androgen withdrawal and irradiation in an androgen sensitive prostate cancer xenograft. Int J Radiat Oncol Biol Phys 1995; 32: 188